Please assess the completion status of the following clinical trial:

Trial Title: PROVOCATION Trial - PROphylactic intraVenOus Hydration for Contrast Agent Toxicity PreventION

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients admitted with renal dysfunction (baseline serum creatinine level above the upper limit of normal of the serum creatinine \[\>93umol/l for women and \>117umol/l for men\] or GFR \<60ml/min \[GFR calculated using the abbreviated MDRD study equation\]) scheduled to undergo an intraarterial or intravenous radiographic contrast procedure within the next 24 hours.~Exclusion Criteria:~* Age \<18 years~* Preexisting dialysis~* Allergy to radiographic contrast~* Pregnancy (women \< 50 years: pregnancy test required)~* Severe heart failure (New York Heart Association \[NYHA\] III-IV)~* N-acetylcysteine \</= 24 hours before contrast~* Clinically vulnerable condition requiring continuous fluid therapy e.g. severe sepsis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): control group: patients receive a preventive hydration with 154mEq/l saline at an ongoing rate of 1ml/kg per hour of at least 12 hours prior and after the procedure.
- 2 (Type: ACTIVE_COMPARATOR): 7h-sodium bicarbonate (according to the regimen used in a recently published study (slightly modified)14): before contrast a bolus of 3ml/kg NaHCO3 166mEq/l for one hour, followed by an infusion of NaHCO3 166mEq/l with a rate of 1ml/kg per hour until 6h after contrast.
- 3 (Type: ACTIVE_COMPARATOR): short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg; patients with a body weight above 100kg 300ml) as a bolus 20 minutes before contrast; additionally ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl of San Pellegrino® non-sparkling mineral water at the start of the infusion. Ingestion of 500ml San Pellegrino® non-sparkling mineral water in the first 6 hours after contrast.

Based on this trial design, predict the completion outcome and termination type (if applicable).